PeptiDream and Genentech Ink $1 Billion Deal for Peptide-RI Drug Conjugates
PeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan, led by President and CEO Patrick C. Reid, has
Read morePeptiDream Inc., a publicly traded biopharmaceutical company headquartered in Kanagawa, Japan, led by President and CEO Patrick C. Reid, has
Read moreThe partnership with Samsung Bioepis Grants Novartis’ generic-drugs unit Sandoz exclusive commercialization rights for biosimilar SB17 Ustekinumab in Europe and
Read moreCustomized Bioconjugation Solutions for Pharma and IVD Industries Biosynth, a pivotal supplier of vital raw materials to the life science
Read moreBiosynth, a leading supplier of critical raw materials to the life science industry, is pleased to announce its recent acquisition
Read moreAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) and PeptiDream Inc. (TSE: 4587, President and CEO: Patrick C.
Read moreWatlow®, a pioneering industrial thermal systems designer and manufacturer, is elevating its digital transformation of energy management and automation solutions
Read moreEli Lilly and Company and DICE Therapeutics, Inc. have signed a definitive agreement for Lilly to acquire DICE for approximately $2.4
Read moreThe $1 billion acquisition deal is set to advance Ironwood’s vision of becoming the leading gastrointestinal healthcare company. Ironwood Pharmaceuticals,
Read moreEisai Co., Ltd. revealed that it has partnered with Bliss Biopharmaceutical (Hangzhou) Co., Ltd. to develop BB-1701, an antibody-drug conjugate
Read moreGSK has entered into an agreement to acquire BELLUS Health, a Canadian late-stage biopharmaceutical company, for a total consideration of
Read more